Tenaya Therapeutics, Inc. cash flow to debt ratio of -630.32% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Tenaya Therapeutics, Inc.'s free cash flow has increased -24.74% from $-91.53M last year to $-68.88M, signaling increasing performance

Tenaya Therapeutics, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Tenaya Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.15 last year to 0.06 today, signaling strengthened financials

Tenaya Therapeutics, Inc. has a net cash position, so leverage is healthy.

Tenaya Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Tenaya Therapeutics, Inc. has insufficient data to evaluate this check.

Tenaya Therapeutics, Inc.'s short-term assets of $105.59M exceed its short-term liabilities of $15.44M

Tenaya Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Tenaya Therapeutics, Inc.'s return on equity of -108.05%, is lower than 15.00%, indicating bad performance

Tenaya Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Tenaya Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Tenaya Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Tenaya Therapeutics, Inc. has negative free cash flow, indicating cash burn

Tenaya Therapeutics, Inc.'s yearly earnings has increased -18.48% since last year from $-111.13M to $-90.60M, signaling increasing performance

Tenaya Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -136.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Tenaya Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Tenaya Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Tenaya Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Tenaya Therapeutics, Inc. has insufficient data to evaluate this check.

Tenaya Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tenaya Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Tenaya Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Tenaya Therapeutics, Inc. has insufficient data to evaluate this check.

Tenaya Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tenaya Therapeutics, Inc. has a price-to-book ratio of 2.31x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Tenaya Therapeutics, Inc. has a price-to-sales ratio of 120.89x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue